First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors GBX 1,503.30 -47.90 (-3.09%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock FBT vs. TRST, PRSM, KAPE, KNOS, LTG, ALFA, GBG, ATG, IMO, and NCCShould you be buying First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? The main competitors of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Trustpilot Group (TRST), Blue Prism Group (PRSM), Kape Technologies (KAPE), Kainos Group (KNOS), Learning Technologies Group (LTG), Alfa Financial Software (ALFA), GB Group (GBG), Auction Technology Group (ATG), IMImobile (IMO), and NCC Group (NCC). These companies are all part of the "software - application" industry. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation vs. Its Competitors Trustpilot Group Blue Prism Group Kape Technologies Kainos Group Learning Technologies Group Alfa Financial Software GB Group Auction Technology Group IMImobile NCC Group Trustpilot Group (LON:TRST) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Is TRST or FBT more profitable? Trustpilot Group has a net margin of 9.02% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Trustpilot Group's return on equity of 29.53% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.Company Net Margins Return on Equity Return on Assets Trustpilot Group9.02% 29.53% 1.45% First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A Do analysts prefer TRST or FBT? Trustpilot Group currently has a consensus price target of GBX 310, suggesting a potential upside of 29.17%. Given Trustpilot Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Trustpilot Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trustpilot Group 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor TRST or FBT? In the previous week, Trustpilot Group's average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score. Company Overall Sentiment Trustpilot Group Neutral First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral Which has stronger earnings and valuation, TRST or FBT? Trustpilot Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Trustpilot Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrustpilot Group£222.55M5.65£20.08M£3.0279.56First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10-1,366.64 Do insiders & institutionals hold more shares of TRST or FBT? 78.2% of Trustpilot Group shares are held by institutional investors. 8.2% of Trustpilot Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryTrustpilot Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 11 of the 11 factors compared between the two stocks. Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBT vs. The Competition Export to ExcelMetricFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationSoftware IndustryComputer SectorLON ExchangeMarket Cap£616.68M£6.25B£29.20B£3.03BDividend YieldN/A3.24%3.08%5.02%P/E Ratio-1,366.6429.2048.09176.75Price / SalesN/A281.641,544.97264,362.43Price / Cash3.5417.1838.0727.97Price / BookN/A11.247.414.53Net IncomeN/A£48.92M£782.10M£5.90B7 Day Performance-0.64%-2.16%-3.65%12.58%1 Month Performance1.88%0.10%-0.11%6.10%1 Year Performance-3.03%7.63%52,642.35%71.59% First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBTFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AGBX 1,503.30-3.1%N/A-2.7%£616.68MN/A-1,366.6420TRSTTrustpilot GroupN/AGBX 260.80+0.3%GBX 310+18.9%+16.8%£1.37B£222.55M86.45820Gap UpPRSMBlue Prism GroupN/AN/AN/AN/A£1.24B£167.30M-23.681,025High Trading VolumeKAPEKape TechnologiesN/AN/AN/AN/A£1.22B£623.48M1,900.00850Gap DownKNOSKainos Group2.9991 of 5 starsGBX 724+0.8%GBX 1,070+47.8%-33.9%£914.49M£383.18M18.972,953News CoverageGap DownLTGLearning Technologies Group3.5681 of 5 starsN/AGBX 90+∞N/A£792.10M£529.20M16.755,001ALFAAlfa Financial Software2.1792 of 5 starsGBX 221+0.7%N/A+14.3%£661.85M£103.11M29.87475News CoverageAnalyst ForecastGap UpGBGGB Group2.5443 of 5 starsGBX 237.50+0.8%GBX 390+64.2%-34.6%£599.04M£276.95M-12.331,183ATGAuction Technology GroupN/AGBX 477.50+2.4%GBX 750+57.1%-4.4%£589.88M£136.68M58.32396Gap UpIMOIMImobileN/AN/AN/AN/A£490.40M£164.04M123.755,300NCCNCC Group1.4615 of 5 starsGBX 146.60flatGBX 175+19.4%+2.1%£462.20M£326.70M-18.462,200Dividend Cut Related Companies and Tools Related Companies Trustpilot Group Competitors Blue Prism Group Competitors Kape Technologies Competitors Kainos Group Competitors Learning Technologies Group Competitors Alfa Financial Software Competitors GB Group Competitors Auction Technology Group Competitors IMImobile Competitors NCC Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FBT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.